Concepedia

Ting Yu

TY

Statistics

Publications

8

Citations

460

H-Index

8

Active since

2007

Affiliations

AstraZeneca (United States)(Current)

The Maria Sklodowska-Curie National Research Institute of Oncology

Vita-Salute San Raffaele University

IRCCS Ospedale San Raffaele

University Hospital Plzen

Ting Yu is an author at AstraZeneca (United States) specializing in chronic lymphocytic leukemia therapy, clinical pharmacology, and medicine.

Publications per year

2007–2025

8

Publications

8

Adipocytokines and breast cancer risk

Weikai Hou, Yuxin Xu, Ting Yu et al. · Chinese Medical Journal · 2007 · 149 citations · Full text

, , +11

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · HemaSphere · 2022 · 103 citations · Full text

, , +14

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak et al. · New England Journal of Medicine · 2025 · 103 citations · Full text

, , +13

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · Journal of Clinical Oncology · 2022 · 26 citations

, , +14

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

Shringi Sharma, Xavier Pépin, Lianqing Zheng et al. · Clinical Pharmacology in Drug Development · 2022 · 26 citations · Full text

, , +14

1–5 of 8